Intravesical instillation therapy for high-risk non-muscle-invasive transitional cell carcinoma of the bladder: Does the strain of Bacillus Calmette-Guerin (BCG) matter?

Phase 3

Completed

• Conditions: on-muscle-invasive transitional cell carcinoma of the bladder; Non-muscle-invasive transitional cell carcinoma of the bladder; Cancer - Bladder

• Registration Number: ACTRN12611000204943
• Lead Sponsor: Department of Urology, Inselspital Bern

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-02-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 149

Inclusion Criteria

High-risk non-muscle-invasive transitional cell carcinoma of the bladder requiring BCG-therapy, complete resection of bladder tumors by TURBT.

Exclusion Criteria

Muscle-invasive transitional cell carcinoma of the bladder, incomplete resection of tumor by TURBT.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor recurrence by cystoscopy and urine cytology[Every 3 months for the first 3 years after the TURBT, then every 6 months until 5 years.];Tumor progression by cystoscopy and urine cytology[Every 3 months for the first 3 years after the TURBT, then every 6 months until 5 years.]

Secondary Outcome Measures

Name	Time	Method
Overall and disease specific survival by phone call to the patient, general practitioner or the familiy.[at the end of the study]